Literature DB >> 21159313

Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome?

Diego Lucero1, Valeria Zago, Graciela I López, Mabel Graffigna, Gustavo H López, Hugo Fainboim, Verónica Miksztowicz, Leonardo Gómez Rosso, Susana Belli, Oscar Levalle, Gabriela Berg, Fernando Brites, Regina Wikinski, Laura Schreier.   

Abstract

BACKGROUND: Hepatic steatosis (HS) is closely associated to metabolic syndrome (MS). Both, VLDL-triglyceride oversecretion and intrahepatic deposits, can take place. We evaluated VLDL characteristics, CETP, hepatic lipase (HL), IDL and small dense LDL (sdLDL), in patients with HS associated to MS.
METHODS: We studied 3 groups matched by age and sex: 25 MS patients with HS (diagnosed by ultrasonography), 25 MS patients without HS and 25 healthy controls. Main measurements were: lipid profile, free fatty acids, VLDL composition, VLDL size by HPLC, CETP and HL activities, IDL-cholesterol and sdLDL-cholesterol.
RESULTS: Patients with HS presented higher triglyceride levels, HOMA-IR and free fatty acids, VLDL mass and VLDL-apoB (p<0.05). No differences in VLDL composition were observed. MS groups presented higher proportion of large VLDL than controls (p<0.05). HS group showed higher CETP than controls (p=0.01) and almost higher than MS without HS (p=0.06). CETP correlated with VLDL-cholesterol content, r=0.48, p<0.005. The increase in sdLDL-cholesterol correlated with CETP (r=0.47) and HL (r=0.56), independent of insulin resistance (p<0.003).
CONCLUSION: Despite intrahepatic fat, patients with HS secreted higher number of VLDL particles. CETP would have a remodeling action on VLDL in circulation, enriching it in cholesterol and also favoring, together with HL, the formation of sdLDL.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159313     DOI: 10.1016/j.cca.2010.12.012

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  9 in total

Review 1.  Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.

Authors:  David E Cohen; Edward A Fisher
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

2.  A new enzyme-linked immunosorbent assay system for human serum hepatic triglyceride lipase.

Authors:  Kazuya Miyashita; Katsuyuki Nakajima; Isamu Fukamachi; Yuji Muraba; Takafumi Koga; Yohnosuke Shimomura; Tetsuyo Machida; Masami Murakami; Junji Kobayashi
Journal:  J Lipid Res       Date:  2017-06-20       Impact factor: 5.922

3.  Characterization of polybrominated diphenyl ether toxicity in Wistar Han rats and use of liver microarray data for predicting disease susceptibilities.

Authors:  June K Dunnick; A Brix; H Cunny; M Vallant; K R Shockley
Journal:  Toxicol Pathol       Date:  2012       Impact factor: 1.902

4.  Both full length-cholesteryl ester transfer protein and exon 9-deleted cholesteryl ester transfer protein promote triacylglycerol storage in cultured hepatocytes.

Authors:  Yan Liu; Daniel Mihna; Lahoucine Izem; Richard E Morton
Journal:  Lipids       Date:  2021-12-05       Impact factor: 1.646

Review 5.  Dyslipidemia: Obese or Not Obese-That Is Not the Question.

Authors:  David H Ipsen; Pernille Tveden-Nyborg; Jens Lykkesfeldt
Journal:  Curr Obes Rep       Date:  2016-12

6.  Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation.

Authors:  Klementina Fon Tacer; Damjana Rozman
Journal:  J Lipids       Date:  2011-07-02

7.  Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet.

Authors:  Victoria Svop Jensen; Christian Fledelius; Erik Max Wulff; Jens Lykkesfeldt; Henning Hvid
Journal:  Nutrients       Date:  2021-02-12       Impact factor: 5.717

8.  A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit.

Authors:  Yi-Wei Liaw; Chi-Yu Lin; Yu-Sheng Lai; Tzu-Chung Yang; Chau-Jong Wang; Jacqueline Whang-Peng; Leroy F Liu; Chia-Po Lin; Shin Nieh; Shao-Chun Lu; Jaulang Hwang
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

Review 9.  Dysregulated lipid metabolism links NAFLD to cardiovascular disease.

Authors:  Audrey Deprince; Joel T Haas; Bart Staels
Journal:  Mol Metab       Date:  2020-10-01       Impact factor: 8.568

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.